The proBNPage reduction (PBAR) trial-results of a randomized, double blind, placebokontrollerad, pilot study to fine tune an NT-proBNP-based method to assess the effect of anti-aging treatments.

Pilotstudien PBAR följde 120 friska personer med medelåldern 71,7 ± 4,6 år i två år. Dess främsta syfte var att utveckla en metod för studiedesign baserad på ”proBNPage”, härlett från NT-proBNP, som ett surrogatmått för biologisk ålder. Deltagarna tilldelades koenzym Q10 100 mg två gånger dagligen plus selen 100 mcg, resveratrol 350 mg två gånger dagligen plus TA-65 100 U eller placebo. The resveratrol plus TA-65 group was stopped at month 5 because LDL cholesterol increased significantly; the abstract says high-dose resveratrol was the probable cause. It does not provide the LDL-cholesterol estimate or p-value. Dropouts and inadequate treatment intake limited the remaining comparisons, and groups receiving coenzyme Q10/selenium or placebo showed no significant differences in proBNPage, step-test duration, handgrip strength or self-reported health. When these two groups were combined, proBNPage increased by 2.5 years after two years (p=0.01), and by 3.0 years in people over 70 (p=0.009). The study did not show that any tested treatment slowed this surrogate measure. It also cannot separate resveratrol from TA-65, and its safety signal argues against high-dose resveratrol in this setting.

The treatments did not induce significant changes in proBNPage, and the marked cholesterol increase suggests high-dose resveratrol should be avoided.